Literature DB >> 7495758

The primary alloresponse of human CD4+ T cells is dependent on B7 (CD80), augmented by CD58, but relatively uninfluenced by CD54 expression.

R Hargreaves1, V Logiou, R Lechler.   

Abstract

Conflicting data have been reported regarding the relative abilities of B7, ICAM-1 and LFA-3 to provide co-stimulation for the induction of a primary T cell alloproliferative response. A series of naturally HLA-DR-expressing cell lines and panels of human and murine transfectants expressing DR alloantigens in conjunction with combinations of mouse or human B7.1, human LFA-3 and human ICAM-1 were used to analyse the contributions of these molecules to primary alloproliferative responses by adult and cord blood CD4+ T cells. The results demonstrated that B7 expression is required, and may be sufficient for the induction of a primary alloresponse. The allostimulation observed in response to DR-expressing murine DAP.3 cells, that constitutively express B7.1, was inhibited by the presence of the murine cytolytic T lymphocyte-associated antigen 4-human Fc gamma 11 fusion protein, suggesting that mouse B7.1 provides sufficient costimulation for a primary human alloproliferative response. Expression of supranormal levels of human B7.1 on the allostimulator cells led to a reduction in the proliferative response, suggesting that an optimal level of B7 exists which, if exceeded, leads to inhibition. Co-expression of LFA-3 with B7.1 by the allostimulator cells caused a marked increase in the proliferative response. Expression of ICAM-1a had relatively little effect. No differences were seen in the co-stimulatory requirements of naive cord blood versus CD45RO adult T cells. There results highlight the key molecular interactions that govern immunogenicity with relevance to inhibiting unwanted immune response to transplanted tissues and provoking anti-tumour immunity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495758     DOI: 10.1093/intimm/7.9.1505

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  6 in total

1.  Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.

Authors:  S J Pettit; S Ali; E O'Flaherty; T R Griffiths; D E Neal; J A Kirby
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM.

Authors:  L Lightstone; R Hargreaves; G Bobek; M Peterson; G Aichinger; G Lombardi; R Lechler
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

Review 3.  Schiff base forming drugs: mechanisms of immune potentiation and therapeutic potential.

Authors:  H Chen; J Rhodes
Journal:  J Mol Med (Berl)       Date:  1996-09       Impact factor: 4.599

4.  n-butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids.

Authors:  G A Böhmig; P M Krieger; M D Säemann; C Wenhardt; E Pohanka; G J Zlabinger
Journal:  Immunology       Date:  1997-10       Impact factor: 7.397

5.  Major histocompatibility complex class II-expressing endothelial cells induce allospecific nonresponsiveness in naive T cells.

Authors:  F M Marelli-Berg; R E Hargreaves; P Carmichael; A Dorling; G Lombardi; R I Lechler
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

Review 6.  CD58 Immunobiology at a Glance.

Authors:  Yalu Zhang; Qiaofei Liu; Sen Yang; Quan Liao
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.